Fuji Pharma Co Ltd
TSE:4554

Watchlist Manager
Fuji Pharma Co Ltd Logo
Fuji Pharma Co Ltd
TSE:4554
Watchlist
Price: 1 458 JPY 2.46% Market Closed
Market Cap: 35.4B JPY
Have any thoughts about
Fuji Pharma Co Ltd?
Write Note

Fuji Pharma Co Ltd
Income from Continuing Operations

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Fuji Pharma Co Ltd
Income from Continuing Operations Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Income from Continuing Operations CAGR 3Y CAGR 5Y CAGR 10Y
Fuji Pharma Co Ltd
TSE:4554
Income from Continuing Operations
ÂĄ6.4B
CAGR 3-Years
26%
CAGR 5-Years
14%
CAGR 10-Years
12%
Takeda Pharmaceutical Co Ltd
TSE:4502
Income from Continuing Operations
ÂĄ290.2B
CAGR 3-Years
-15%
CAGR 5-Years
28%
CAGR 10-Years
12%
Daiichi Sankyo Co Ltd
TSE:4568
Income from Continuing Operations
ÂĄ250.7B
CAGR 3-Years
42%
CAGR 5-Years
17%
CAGR 10-Years
14%
Otsuka Holdings Co Ltd
TSE:4578
Income from Continuing Operations
ÂĄ155.2B
CAGR 3-Years
1%
CAGR 5-Years
5%
CAGR 10-Years
-1%
Chugai Pharmaceutical Co Ltd
TSE:4519
Income from Continuing Operations
ÂĄ387B
CAGR 3-Years
15%
CAGR 5-Years
23%
CAGR 10-Years
22%
Astellas Pharma Inc
TSE:4503
Income from Continuing Operations
ÂĄ54.6B
CAGR 3-Years
-18%
CAGR 5-Years
-25%
CAGR 10-Years
-6%
No Stocks Found

Fuji Pharma Co Ltd
Glance View

Market Cap
35.4B JPY
Industry
Pharmaceuticals

Fuji Pharma Co., Ltd. engages in the development, manufacture and sale of pharmaceutical products. The company is headquartered in Chiyoda-Ku, Tokyo-To and currently employs 1,532 full-time employees. The firm is engaged in the manufacture and sale of hormone medicines for obstetrics and gynecology department, as well as injectable drugs for radiological department such as radiopaque dye for urinary tracts and blood vessels through its branches. In addition, the Company purchases its main pharmaceutical ingredients from its main parent company.

Intrinsic Value
2 002.38 JPY
Undervaluation 27%
Intrinsic Value
Price

See Also

What is Fuji Pharma Co Ltd's Income from Continuing Operations?
Income from Continuing Operations
6.4B JPY

Based on the financial report for Jun 30, 2024, Fuji Pharma Co Ltd's Income from Continuing Operations amounts to 6.4B JPY.

What is Fuji Pharma Co Ltd's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 10Y
12%

Over the last year, the Income from Continuing Operations growth was 212%. The average annual Income from Continuing Operations growth rates for Fuji Pharma Co Ltd have been 26% over the past three years , 14% over the past five years , and 12% over the past ten years .

Back to Top